Bank of New York Mellon’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-267,627
| Closed | -$13.8M | – | 4620 |
|
|
2022
Q3 | $13.8M | Buy |
267,627
+29,401
| +12% | +$1.22M | ﹤0.01% | 1705 |
|
|
2022
Q2 | $5.9M | Sell |
238,226
-48,670
| -17% | -$1.07M | ﹤0.01% | 2226 |
|
|
2022
Q1 | $7.19M | Sell |
286,896
-8,902
| -3% | -$250K | ﹤0.01% | 2250 |
|
|
2021
Q4 | $10.8M | Sell |
295,798
-239
| -0.1% | -$8.39K | ﹤0.01% | 2066 |
|
|
2021
Q3 | $5.06M | Buy |
296,037
+14,145
| +5% | +$220K | ﹤0.01% | 2479 |
|
|
2021
Q2 | $3.77M | Buy |
281,892
+70,405
| +33% | +$1.73M | ﹤0.01% | 2630 |
|
|
2021
Q1 | $10.8M | Sell |
211,487
-6,981
| -3% | -$420K | ﹤0.01% | 2044 |
|
|
2020
Q4 | $13.5M | Sell |
218,468
-3,986
| -2% | -$228K | ﹤0.01% | 1842 |
|
|
2020
Q3 | $12.2M | Buy |
222,454
+10,683
| +5% | +$575K | ﹤0.01% | 1742 |
|
|
2020
Q2 | $12.2M | Buy |
211,771
+10,678
| +5% | +$581K | ﹤0.01% | 1716 |
|
|
2020
Q1 | $8.08M | Sell |
201,093
-6,432
| -3% | -$273K | ﹤0.01% | 1811 |
|
|
2019
Q4 | $8.21M | Buy |
207,525
+28,389
| +16% | +$498K | ﹤0.01% | 2088 |
|
|
2019
Q3 | $1.22M | Buy |
179,136
+4,226
| +2% | +$31.7K | ﹤0.01% | 3056 |
|
|
2019
Q2 | $1.63M | Buy |
174,910
+41,291
| +31% | +$478K | ﹤0.01% | 2919 |
|
|
2019
Q1 | $1.86M | Sell |
133,619
-6,186
| -4% | -$70.7K | ﹤0.01% | 2810 |
|
|
2018
Q4 | $1.52M | Buy |
139,805
+12,957
| +10% | +$137K | ﹤0.01% | 2865 |
|
|
2018
Q3 | $1.6M | Buy |
126,848
+8,070
| +7% | +$97.2K | ﹤0.01% | 2987 |
|
|
2018
Q2 | $1.56M | Buy |
118,778
+12,158
| +11% | +$145K | ﹤0.01% | 2995 |
|
|
2018
Q1 | $1.45M | Sell |
106,620
-4,266
| -4% | -$44K | ﹤0.01% | 3000 |
|
|
2017
Q4 | $660K | Buy |
110,886
+324
| +0.3% | +$2.22K | ﹤0.01% | 3474 |
|
|
2017
Q3 | $821K | Buy |
110,562
+3,947
| +4% | +$32.8K | ﹤0.01% | 3336 |
|
|
2017
Q2 | $998K | Sell |
106,615
-1,010
| -0.9% | -$7.41K | ﹤0.01% | 3255 |
|
|
2017
Q1 | $784K | Sell |
107,625
-1,373
| -1% | -$9.89K | ﹤0.01% | 3375 |
|
|
2016
Q4 | $806K | Buy |
108,998
+4,100
| +4% | +$29.5K | ﹤0.01% | 3374 |
|
|
2016
Q3 | $633K | Sell |
104,898
-12,367
| -11% | -$58.4K | ﹤0.01% | 3422 |
|
|
2016
Q2 | $526K | Buy |
117,265
+22,314
| +24% | +$83.7K | ﹤0.01% | 3514 |
|
|
2016
Q1 | $236K | Buy |
94,951
+14,895
| +19% | +$54.2K | ﹤0.01% | 3733 |
|
|
2015
Q4 | $648K | Sell |
80,056
-5,604
| -7% | -$39.7K | ﹤0.01% | 3413 |
|
|
2015
Q3 | $519K | Sell |
85,660
-28,758
| -25% | -$208K | ﹤0.01% | 3573 |
|
|
2015
Q2 | $942K | Buy |
114,418
+4,419
| +4% | +$35.1K | ﹤0.01% | 3369 |
|
|
2015
Q1 | $830K | Hold |
109,999
| – | – | ﹤0.01% | 3396 |
|
|
2014
Q4 | $751K | Sell |
109,999
-1,164
| -1% | -$6.16K | ﹤0.01% | 3455 |
|
|
2014
Q3 | $500K | Hold |
111,163
| – | – | ﹤0.01% | 3626 |
|
|
2014
Q2 | $650K | Sell |
111,163
-191
| -0.2% | -$1.07K | ﹤0.01% | 3524 |
|
|
2014
Q1 | $739K | Buy |
111,354
+10,220
| +10% | +$71K | ﹤0.01% | 3425 |
|
|
2013
Q4 | $585K | Buy |
101,134
+3,548
| +4% | +$18.3K | ﹤0.01% | 3523 |
|
|
2013
Q3 | $543K | Buy |
97,586
+2,890
| +3% | +$31.3K | ﹤0.01% | 3489 |
|
|
2013
Q2 | $1.34M | Buy |
+94,696
| New | +$1.23M | ﹤0.01% | 3016 |
|
Other funds holding CCXI
Bank of New York Mellon's CCXI Position: Q4 2022 in Review
Bank of New York Mellon sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 267,627 shares — an estimated $13.8M sold.
Bank of New York Mellon first reported a position in CCXI in Q2 2013 and held it in 38 quarters. The position peaked at $13.8M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Bank of New York Mellon reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Bank of New York Mellon sold 267,627 ChemoCentryx, Inc. shares in Q4 2022, an estimated $13.8M.
- Bank of New York Mellon first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 38 quarters.
- Bank of New York Mellon's ChemoCentryx, Inc. position peaked at $13.8M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.